Focal mass drug administration (fMDA) to reduce Plasmodium vivax transmission, a pragmatic cluster randomized controlled trial in Peru

旨在减少间日疟原虫传播的集中集中药物管理(fMDA),这是秘鲁的一项实用整群随机对照试验

基本信息

项目摘要

Project Summary/Abstract In most countries approaching elimination, Plasmodium vivax (Pv) represents an increasing proportion relative to P. falciparum (Pf). Mass drug administration (MDA), as a way target subpatent, asymptomatic infections, is recommended for P. falciparum elimination, but the recommendation does not extend to P. vivax given limited evidence, tools, and safety concerns. The objective of our study is to evaluate the long-term impact, safety, and cost-effectiveness of focal MDA (fMDA) for Pv transmission reduction. To test our hypothesis that fMDA, in addition to standard aggressive interventions, will safely reduce transmission, we propose a 3-year open-label CRCT in the low endemic setting of Loreto Region, Peru. Villages or clusters will be randomized to control or fMDA. The control arm will receive standard interventions (vector control, symptomatic case management, and active case detection of asymptomatic cases). The treatment arm will receive standard interventions plus fMDA, which will utilize a new drug for radical cure of P. vivax, tafenoquine, and a new quantitative glucose 6 phosphate dehydrogenase (G6PD) deficiency rapid test to support safe administration of tafenoquine. fMDA will be targeted to consenting and eligible high-risk villagers, defined as household members and neighbors of recent Pv index cases. fMDA will be conducted in 2 rounds per year, two months apart during the low malaria season, and over 3 years. Eligibility will be re-assessed each year, and prior to each fMDA round. Specific aims are to: 1) Determine the effectiveness of fMDA to reduce Pv transmission as measured in a primary outcome of incidence and secondary outcomes of infection prevalence, seroprevalence, and genetic diversity, 2) Evaluate the safety and tolerability of fMDA, and 3) Measure the cost-effectiveness of fMDA. To maximize
项目概要/摘要 在大多数接近消除的国家,间日疟原虫 (Pv) 的比例相对不断增加 恶性疟原虫(Pf)。大规模药物管理(MDA)作为针对亚专利、无症状感染者的一种方式, 建议用于消除恶性疟原虫,但鉴于有限,该建议不适用于间日疟原虫 证据、工具和安全问题。我们研究的目的是评估长期影响、安全性、 以及用于减少光伏传输的焦点 MDA (fMDA) 的成本效益。为了检验我们的假设,即 fMDA, 除了标准的积极干预措施外,为了安全地减少传播,我们提出了为期 3 年的开放标签 秘鲁洛雷托地区低流行环境下的 CRCT。村庄或集群将被随机分组​​以进行控制或 fMDA。控制臂将接受标准干预措施(病媒控制、症状病例管理和 主动发现无症状病例)。治疗组将接受标准干预措施加上 fMDA, 它将利用一种新药来根治间日疟原虫,他非诺喹和一种新的定量葡萄糖 6 磷酸脱氢酶 (G6PD) 缺乏症快速检测,支持他非诺喹的安全给药。丙二醛 将针对同意且符合条件的高风险村民,定义为家庭成员和邻居 最近的 Pv 指数案例。 fMDA 将每年进行 2 轮,在低疟疾期间间隔两个月 季节,并超过3年。每年都会在每轮 fMDA 之前重新评估资格。具体的 目标是: 1) 确定 fMDA 减少 Pv 传输(在一次测量中测量)的有效性 发病率结果和感染流行率、血清流行率和遗传多样性的次要结果, 2) 评估 fMDA 的安全性和耐受性,以及 3) 衡量 fMDA 的成本效益。最大化

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Michelle Sang Hsiang其他文献

Michelle Sang Hsiang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Michelle Sang Hsiang', 18)}}的其他基金

Focal mass drug administration (fMDA) to reduce Plasmodium vivax transmission, a pragmatic cluster randomized controlled trial in Peru
旨在减少间日疟原虫传播的集中集中药物管理(fMDA),这是秘鲁的一项实用整群随机对照试验
  • 批准号:
    10488139
  • 财政年份:
    2022
  • 资助金额:
    $ 126.14万
  • 项目类别:
Long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania
针对坦桑尼亚儿童低密度疟疾感染(LMI)的干预措施的长期健康和社会经济影响
  • 批准号:
    10609863
  • 财政年份:
    2022
  • 资助金额:
    $ 126.14万
  • 项目类别:
Long-term health and socioeconomic impact of interventions targeting low-density malaria infection (LMI) among children in Tanzania
针对坦桑尼亚儿童低密度疟疾感染(LMI)的干预措施的长期健康和社会经济影响
  • 批准号:
    10328848
  • 财政年份:
    2022
  • 资助金额:
    $ 126.14万
  • 项目类别:
Evaluating Re-active Surveillance Strategies for Malaria Elimination in Swaziland
评估斯威士兰消除疟疾的反应性监测策略
  • 批准号:
    8471646
  • 财政年份:
    2012
  • 资助金额:
    $ 126.14万
  • 项目类别:
Evaluating Re-active Surveillance Strategies for Malaria Elimination in Swaziland
评估斯威士兰消除疟疾的反应性监测策略
  • 批准号:
    9085213
  • 财政年份:
    2012
  • 资助金额:
    $ 126.14万
  • 项目类别:
Evaluating Re-active Surveillance Strategies for Malaria Elimination in Swaziland
评估斯威士兰消除疟疾的反应性监测策略
  • 批准号:
    8662187
  • 财政年份:
    2012
  • 资助金额:
    $ 126.14万
  • 项目类别:
Evaluating Re-active Surveillance Strategies for Malaria Elimination in Swaziland
评估斯威士兰消除疟疾的反应性监测策略
  • 批准号:
    8862355
  • 财政年份:
    2012
  • 资助金额:
    $ 126.14万
  • 项目类别:
Evaluating Re-active Surveillance Strategies for Malaria Elimination in Swaziland
评估斯威士兰消除疟疾的反应性监测策略
  • 批准号:
    8354419
  • 财政年份:
    2012
  • 资助金额:
    $ 126.14万
  • 项目类别:

相似海外基金

Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations
药房主导的护理干预转型,以解决系统层面的障碍并提高社会经济弱势群体的药物依从性
  • 批准号:
    10594350
  • 财政年份:
    2023
  • 资助金额:
    $ 126.14万
  • 项目类别:
Evaluating Centralizing Interventions to Address Low Adherence to Lung Cancer Screening Follow-up in Decentralized Settings
评估集中干预措施,以解决分散环境中肺癌筛查随访依从性低的问题
  • 批准号:
    10738120
  • 财政年份:
    2023
  • 资助金额:
    $ 126.14万
  • 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
  • 批准号:
    10526768
  • 财政年份:
    2022
  • 资助金额:
    $ 126.14万
  • 项目类别:
Suubi-Mhealth: A mobile health intervention to address depression and improve ART adherence among Youth living with HIV (YLHIV) in Uganda
Suubi-Mhealth:一种移动健康干预措施,旨在解决乌干达艾滋病毒感染者 (YLHIV) 青少年的抑郁症问题并提高抗逆转录病毒疗法的依从性
  • 批准号:
    10701072
  • 财政年份:
    2022
  • 资助金额:
    $ 126.14万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10679092
  • 财政年份:
    2021
  • 资助金额:
    $ 126.14万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10432133
  • 财政年份:
    2021
  • 资助金额:
    $ 126.14万
  • 项目类别:
A behavioral intervention for Black men who have sex with men and live with HIV to address intersectional stigma and improve antiretroviral therapy adherence
针对男男性行为且感染艾滋病毒的黑人男性进行行为干预,以解决交叉耻辱并提高抗逆转录病毒治疗的依从性
  • 批准号:
    10327065
  • 财政年份:
    2021
  • 资助金额:
    $ 126.14万
  • 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
  • 批准号:
    10377366
  • 财政年份:
    2019
  • 资助金额:
    $ 126.14万
  • 项目类别:
Leveraging Technology to Address Access and Adherence to Conventional Hospital-Based Pulmonary Rehabilitation in Veterans with COPD
利用技术解决慢性阻塞性肺病退伍军人接受和坚持传统医院肺康复的问题
  • 批准号:
    10574496
  • 财政年份:
    2019
  • 资助金额:
    $ 126.14万
  • 项目类别:
Targeted interventions to address the multi-level effects of gender-based violence on PrEP uptake and adherence among adolescent girls and young women in Kenya
有针对性的干预措施,以解决性别暴力对肯尼亚少女和年轻妇女接受和坚持 PrEP 的多层面影响
  • 批准号:
    9403567
  • 财政年份:
    2017
  • 资助金额:
    $ 126.14万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了